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­effectiveness­ of­ public­ health­ policies­ and­ to­ assess­ the­







In­ the­USA,­ typical­ examples­ of­ public­ data­ on­medical­
outcomes­ are­ the­ Surveillance,­ Epidemiology­ and­ End­ Re-
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al­ Thoracic­ Surgery­ and­Outcomes­ Report­ (8)­ and­ France’s­








instruments­of­ risk­assessment­ for­ thoracic­ surgery­ institu-
tions­(11,­12).
In­ Italy,­ an­ official­ agency­ of­ the­Ministry­ of­ Health,­ the­
Agenzia Nazionale per i Servizi Sanitari Regionali­ (AGENAS),­
provided­ 30-day­ mortality­ statistics­ after­ major­ surgical­ or­
medical­procedures­for­each­Italian­hospital­over­a­period­of­
6­years­(2008-2013)­based­on­administrative­data­such­as­dis-




















variety­of­ operative­procedures­ classified­as­ anatomical­ re-
sections­ (pneumonectomy,­ lobectomy,­ segmentectomy)­ or­
non-anatomical­ sublobar­ resections,­ including­ wedge­ and­
precision­resections.­ In­addition,­the­procedures­performed­
were­classified­as­simple­(i.e.,­not­associated­with­other­re-
sections)­ or­ complex­ (associated­ with­ resections­ of­ adja-
cent­ structures,­ organ­ replacement­ or­ reconstruction).­ For­
patients­with­primary­lung­cancer,­simple­anatomical­resec-
tions­always­included­systematic­dissection­of­multiple­hilar­
and­mediastinal­ lymph-node­ stations.­All­ anatomical­ resec-
tions­ for­primary­ lung­cancer­were­staged­according­ to­ the­
7th­ edition­of­ the­ International­Association­ for­ the­Study­of­
Lung­Cancer­(IASLC)­staging­system­(14).­All­information­relat-
ing­ to­ the­period­of­ hospitalization­were­ validated­ through­
the­medical­record­register,­particularly­for­patients­who­died­
during­hospitalization.








Survival in thoracic surgery98­
30-day­mortality,­and­Kaplan-Meier­estimate­of­5-year­surviv-
al)­were­calculated.
Outcomes­ were­ stratified­ according­ to­ (i)­ cancer­ type­
(primary­ lung­ cancer,­ lung­metastases,­ and­other­malignan-
cies),­(ii)­resection­volume­(pneumonectomy,­lobectomy,­seg-
mentectomy,­ and­ wedge­ or­ precision­ sublobar­ resections),­
(iii)­complexity­of­resection­(simple­or­complex),­and­(iv)­path-
ological­TNM­stage.
Additionally,­ we­ calculated­ the­ 95%­ confidence­ inter-










The­ INTM­ Medical­ Directorate­ checked­ the­ in-hospital­
deaths.­All­other­deaths­were­retrieved­through­record­link-










Of­ the­ 7,602­ thoracic­ surgical­ procedures­ recorded­ at­
INTM­ from­ January­ 2003­ to­ December­ 2015,­ 4,857­ (64%)­
were­pulmonary­resections­and­4,234­(87%)­represented­the­
first­ surgical­ procedure­ (Fig.­ 1).­ The­ remaining­ 623­ subse-
quent­lung­resections­were­not­included­in­the­analysis.
The­ patients’­ characteristics­ are­ illustrated­ in­ Table­ I.­
Out­ of­ 4,234­ first­ pulmonary­ resections,­ 259­ (6.1%)­ were­
performed­ for­ benign­ diseases.­ Among­ the­ 3,975­ patients­
(93.9%)­with­malignant­ tumors,­ 2,636­ (66.3%)­had­primary­
lung­cancer,­1,080­(27.2%)­ lung­metastases,­and­259­(6.5%)­





Table­ II­ shows­ the­ 30-day­ mortality­ in­ patients­ with­




mortality­ (0.3%),­ independent­ of­ the­ resection­ volume.­
Pneumonectomy­was­associated­with­a­significantly­higher­
mortality­rate­(3.5%)­than­lobectomy­(1%),­segmentectomy­










also­ shows­ the­ 30-day­ mortality­ according­ to­ pathologi-
cal­ tumor­ stage­ in­ 2,376­ lung­ cancer­ patients­ undergoing­
anatomical­ resections.­ Stage­ I­ lung­ cancer­ had­ a­ signifi-
cantly­ lower­mortality­ than­higher­stages­ (0.7%­vs.­1.6%),­








TABLE I - Selected­cohort­characteristics­in­patients­with­malignant­tumors­according­to­cancer­type
Overall Lung cancer Metastasis Other
(N = 3,975) (N = 2,636) (N = 1,080) (N = 259)
Sex
 Female, n (%) 1,464 (36.8) 888 (33.7) 478 (44.3) 98 (37.8)
 Male, n (%) 2,511 (63.2) 1,748 (66.3) 602 (55.7) 161 (62.2)
Age, mean (SD), years 61.7 (13.0) 64.9 (10.6) 56.0 (14.5) 52.9 (15.7)
Body mass index, mean (SD)‡ 25.6 (3.9) 25.61 (3.9) 26.03 (2.8) 25.68 (0.3)
Resection volume
 Pneunomectomy, n (%) 367 (9.2) 261 (9.9) 11 (1.0) 95 (36.7)
 Lobectmy, n (%) 2,027 (50.9) 1,845 (69.9) 141 (13.1) 41 (15.8)
 Segmentectomy, n (%) 390 (9.8) 270 (10.2) 113 (10.5) 7 (2.7)
 Wedge/precision, n (%) 1,191 (29.9) 260 (9.9) 815 (75.5) 116 (44.8)
‡ Missing data are hidden.
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In­ summary,­ the­ highest­mortality­ was­ observed­ in­ pa-






(Tab.­ III),­ being­ longer­ for­ primary­ tumors­ other­ than­ lung­
cancer­ (9­ days)­ and­pneumonectomies­ (8­ days),­ and­ short-





were­ accumulated­ by­ patients­ with­ malignant­ tumors­ and­
1,870­ deaths­ occurred­ during­ the­ follow-up­ period,­ with­ a­
mortality­ rate­ for­ all­ causes­ of­ 11.5/100­ person-years.­ The­
5-year­survival­according­to­cancer­type­showed­a­significant­
difference­between­patients­with­lung­cancer,­other­primary­
malignancies,­ and­ lung­metastases,­ with­ a­ cumulative­ sur-




































































































































































































































































































































































































LC META Other Total
Pneumonectomy Median (IQR) 7 (4) 7 (5) 12 (10) 8 (6)
N 261 11 95 367
Lobectomy Median (IQR) 6 (4) 6 (2) 8 (6) 6 (4)
N 1,845 141 41 2,027
Segmentectomy Median (IQR) 6 (3) 5 (1) 5 (7) 6 (2)
N 270 113 7 390
Wedge/precision Median (IQR) 5 (3) 5 (2) 7 (6) 5 (2)
N 260 815 116 1,191
Total Median (IQR) 6 (3) 5 (2) 9 (7) 6 (3)
N 2,636 1,080 259 3,975
IQR = interquartile range; LC = lung cancer; META = lung metastasis; N = 
number.
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TABLE IV -  Adjusted­hazard­ratios­and­95%­confidence­intervals­ac-
cording­to­different­settings
HR* (95% CI)
HR (95% CI) according to cancer type: primary 





HR (95% CI) in LC patients according to ana-





HR (95% CI) in LC patients according to anatomi-
cal resections and complexity of procedure
 Lobe./Segment. SIMPLE 1.00 (reference)
 Lobe./Segment. COMPLEX 1.67 (1.42-1.96)
 Pneumo. SIMPLE 1.96 (1.48-2.59)
 Pneumo. COMPLEX 2.59 (2.08-3.23)
HR (95% CI) in LC patients with simple ana-
tomical resections according to pathological 
stage
 Stage I 1.00 (reference)
 Stage II 2.11 (1.75-2.55)
 Stage III-IV 3.57 (3.04-4.18)
HR (95% CI) in LC patients with complex anatom-
ical resections according to pathological stage
 Stage I 1.00 (reference)
 Stage II 2.10 (1.40-3.15)
 Stage III-IV 3.43 (2.35-4.99)
CI = confidence interval; HR = hazard ratio; LC = lung cancer; Lobe. = lobec-
tomy; Pneumo. = pneumonectomy; Segment. = segmentectomy.
* Adjusted for age and sex.
Fig. 2 -­ Five-year­ survival­ according­ to­ cancer­
type:­primary­lung­cancer­(LC),­lung­metastases­
(META),­and­other­malignancies­(Other).
Finally,­ 5-year­ survival­ by­ pathological­ tumor­ stage­ con-










lung­ cancer­ survival­ of­ anatomical­ resections­ ­according­ to­
pathological­stage­in­patients­with­complex­resections.­Avail-
able­ online­ at­ www.tumorijournal.com).­ The­ independent­





Real-world­ medicine,­ as­ opposed­ to­ evidence-based­
medicine­generated­by­prospective­randomized­trials,­mainly­
refers­to­the­retrospective­evaluation­of­large­unselected­se-
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Fig. 3 -­Five-year­lung­cancer­survival­





according­ to­ anatomical­ resections­
and­procedure­complexity.
provide­ updated­outcome­ indicators­ to­ be­ shared­with­ pa-
tients.­ In­order­ to­avoid­ retrospective­ clinical­ selection­and­
potential­ biases,­ an­ institutional­ audit­ should­ identify­ all­
treated­patients­within­a­given­period­through­independent­
medical­and­administrative­databases,­regardless­of­their­pri-







overall­ health-care­ quality­ (11),­ our­ outcome­ analysis­ was­
based­on­all-cause­mortality,­which­represents­the­most­solid­
endpoint­ for­ this­ type­of­ institutional­audit.­ In­contrast­with­
the­majority­of­surgical­series,­where­follow-up­was­obtained­
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risk­modifiers­such­as­concurrent­chronic­diseases,­cardiopul-
monary­ function­and­medical­ comorbidity­ is­a­ limitation­of­
the­present­audit­(16,­17),­but­these­data­were­not­available­
for­ a­ significant­ proportion­ of­ patients.­ It­ is­ our­ intention,­




In­ general­ terms,­ our­ results­ confirm­ that­ overall­ 30-day­
mortality­ in­thoracic­surgery­has­declined­ in­the­ last­20­years­
(Tab.­V),­but­there­are­still­significant­variations­among­different­
series,­even­in­the­last­decade.­In­fact,­the­1.3%­value­observed­





population-based­ series­ is­ substantial,­our­95%­CIs­of­30-day­
mortality­confirm­the­favorable­trend­(Tab.­IV).
In­the­specific­Italian­scenario,­our­overall­30-day­mortal-





First author (ref.) Years Number Overall Lobectomy Pneumonectomy
Birkmeyer (3) 1994-1999 16,785 7.6 6.4 17
Pastorino (19) 1998-2002 1,418 1.8 1.7 3.7
Kozower (16) 2002-2008 18,800 2.2 - -
Falcoz (9) 2005-2010 19,556 7.4 6.1 12.9
Hu (1) 2006-2010 11,787 3.7 - -
Brunelli (18) 2007-2015 47,960 2.7 2.3 6.8
Present series 2003-2015 2,636 1.2 1.1 3.1
­national­value­published­by­AGENAS,­showing­a­gradual­de-





































vided­ by­ this­ audit­ is­ the­ correlation­ between­ short-term­
mortality­ and­ long-term­outcome­ of­ surgical­ resections­ for­
























Non-anatomical­ sublobar­ resections­ or­ lobectomies­
without­ hilar­ and­ mediastinal­ lymph­ node­ dissection­ may­
be­linked­to­a­0.5%­to­1%­reduction­of­30-day­mortality,­but­
the­SEER­reports­clearly­demonstrate­that­the­ultimate­cost­
of­ suboptimal­ surgery­ for­ primary­ lung­ cancer­ is­ a­ 10%­ to­
20%­reduction­of­5-year­survival­(2,­4).­In­the­present­series,­








In­ conclusion,­ 30-day­ mortality­ in­ thoracic­ surgery­ is­
significantly­ associated­with­ the­ type­ and­ stage­ of­ disease,­
lung­resection­volume,­and­complexity­of­surgical­procedure.­
Postoperative­ mortality­ and­ 5-year­ survival­ are­ 2­ comple-
mentary­measures­of­performance,­and­for­better­monitor-
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